Brief: Everest Medicines & Providence Enter Into COVID-19 Vaccines License Agreement
13/09/2021 10:02
Sept 13 (Reuters) - Everest Medicines Ltd 1952.HK :
* CO AND PROVIDENCE ENTERED INTO COVID-19 VACCINES LICENSE
AGREEMENT
* SHALL PAY PROVIDENCE UPFRONT NON-REFUNDABLE FEE OF US$50
MILLION
WITHIN 30 DAYS OF EXECUTION OF LICENSE AGREEMENT
* TO ISSUE AN AGGREGATE OF UP TO 41.9 MILLION SHARES WITH A
COMBINED AGGREGATE VALUE OF UP TO HK$2,333 MILLION TO SATISFY
MILESTONE PAYMENTS
Source text for Eikon: ID:nHKS2x5SrW
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region